BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Brain cancer AND BRCA2, FAD, 675, ENSG00000139618, FACD, FAD1, FANCD, FANCD1, BRCC2, RP11-298P3_4 AND Treatment
16178 results:

  • 1. Determining Ideal Management for Patients With Coexisting Prolactinomas and Psychiatric Symptoms: A Systematic Review.
    Paracha A; Durrani U; Vasireddy S; Abid A; Waheed F; Thomure M
    J Psychiatr Pract; 2024 May; 30(3):200-211. PubMed ID: 38819244
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Juglone triggers apoptosis of non-small cell lung cancer through the reactive oxygen species -mediated PI3K/Akt pathway.
    Zhong J; Hua Y; Zou S; Wang B
    PLoS One; 2024; 19(5):e0299921. PubMed ID: 38814975
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. MGMT inhibition regulates radioresponse in GBM, GSC, and melanoma.
    Yun HS; Kramp TR; Palanichamy K; Tofilon PJ; Camphausen K
    Sci Rep; 2024 May; 14(1):12363. PubMed ID: 38811596
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Predictors of early and late postoperative seizures in meningioma patients: a systematic review and meta-analysis.
    Ghazou A; Yassin A; Aljabali AS; Al-Zamer YS; Alawajneh M; Al-Akhras A; AlBarakat MM; Tashtoush S; Shammout O; Al-Horani SS; Jarrah EE; Ababneh O; Jaradat A
    Neurosurg Rev; 2024 May; 47(1):242. PubMed ID: 38806755
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Epithelial ovarian cancer and brain metastases: might the
    Sassu CM; Marchetti C; Russo G; Minucci A; Boccia SM; Benato A; Nero C; Piermattei A; Mattogno PP; Giannarelli D; Ferrandina G; Olivi A; Fagotti A; Scambia G
    Int J Gynecol Cancer; 2024 Jan; 34(1):88-98. PubMed ID: 38805344
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Optic nerve sheath diameter correlates with both success and failure of hydrocephalus treatment in pediatric patients with pineal region lesions.
    Zipfel J; Kerscher SR; Dhillon K; Ferraris KP; Singhal A
    Acta Neurochir (Wien); 2024 May; 166(1):236. PubMed ID: 38805061
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Multifunctional elastin-like polypeptide nanocarriers for efficient miRNA delivery in cancer therapy.
    Hong J; Sim D; Lee BH; Sarangthem V; Park RW
    J Nanobiotechnology; 2024 May; 22(1):293. PubMed ID: 38802812
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Tumour growth rate predicts overall survival in patients with recurrent WHO grade 4 glioma.
    Pang JHW; Saffari SE; Lee GR; Yu WY; Lim CCT; Lim KC; Lee CC; Koh WY; Chia WTD; Chua KLM; Tham CK; Low YYS; Ng WH; Low CYD; Lin X
    BMC Med Imaging; 2024 May; 24(1):125. PubMed ID: 38802734
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Thyrotropin-secreting pituitary adenomas: clinical features and results of treatment in 45 patients].
    Trukhina DA; Przhiyalkovskaya EG; Belaya ZE; Grigoriev AY; Azizyan VN; Mamedova EO; Rozhinskaya LY; Lapshina AM; Pigarova EA; Dzeranova LK; Platonova NM; Troshina EA; Melnichenko GA
    Probl Endokrinol (Mosk); 2023 Sep; 70(2):23-36. PubMed ID: 38796758
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer patients with brain metastases from the randomized DESTINY-Breast03 trial.
    Hurvitz SA; Kim SB; Chung WP; Im SA; Park YH; Hegg R; Kim MH; Tseng LM; Petry V; Chung CF; Iwata H; Hamilton E; Curigliano G; Xu B; Egorov A; Liu Y; Cathcart J; Bako E; Tecson K; Verma S; Cortés J
    ESMO Open; 2024 May; 9(5):102924. PubMed ID: 38796287
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Fluorescein-guided surgery in high-grade gliomas: focusing on the eloquent and deep-seated areas.
    Xiao Y; Li M; Wang X; Tan J; Qin C; Liu Q
    J Cancer Res Clin Oncol; 2024 May; 150(5):274. PubMed ID: 38795238
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. cancer-associated stroke from progressive acinic cell carcinoma.
    Garcia JJB; Pascual JLV
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38789271
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy.
    Kilickap S; Ozturk A; Karadurmus N; Korkmaz T; Yumuk PF; Cicin I; Paydas S; Cilbir E; Sakalar T; Uysal M; Yesil Cinkir H; Uskent N; Demir N; Sakin A; Dursun OU; Aver B; Turhal NS; Keskin S; Tural D; Eralp Y; Bugdayci Basal F; Yasar HA; Sendur MAN; Demirci U; Cubukcu E; Karaagac M; Cakar B; Tatli AM; Yetisyigit T; Urvay S; Gursoy P; Oyan B; Turna ZH; Isikdogan A; Olmez OF; Yazici O; Cabuk D; Seker MM; Unal OU; Meydan N; Okutur SK; Tunali D; Erman M;
    Medicine (Baltimore); 2024 May; 103(21):e37972. PubMed ID: 38787994
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. The efficiency and safety of temozolomide and PD-1/L1 inhibitors in pretreated NSCLC with brain metastasis: a retrospective cohort.
    Li X; Wu D; Tang J; Wu Y
    J Cancer Res Clin Oncol; 2024 May; 150(5):271. PubMed ID: 38780840
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Synchronous skull base and spinal metastases in a patient with treatment-resistant, high-grade serous adenocarcinoma of tubo-ovarian origin.
    Ziegler J; El-Shakankery KH; Hyare H; Flynn M
    BMJ Case Rep; 2024 May; 17(5):. PubMed ID: 38772871
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Accelerating diabetic wound healing by ROS-scavenging lipid nanoparticle-mRNA formulation.
    Wang S; Zhang Y; Zhong Y; Xue Y; Liu Z; Wang C; Kang DD; Li H; Hou X; Tian M; Cao D; Wang L; Guo K; Deng B; McComb DW; Merad M; Brown BD; Dong Y
    Proc Natl Acad Sci U S A; 2024 May; 121(22):e2322935121. PubMed ID: 38771877
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Curcumin affects autophagy of prolactinoma cells by upregulating miR-206 to exert antitumor effects.
    Duan JF; Zhang QJ; Zhu J; Lu JH
    J Biochem Mol Toxicol; 2024 Jun; 38(6):e23734. PubMed ID: 38764151
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Safety and efficacy of inebilizumab for the treatment of neuromyelitis optica spectrum disorder: end-of-study results from the open-label period of the N-MOmentum trial.
    Cree BAC; Kim HJ; Weinshenker BG; Pittock SJ; Wingerchuk DM; Fujihara K; Paul F; Cutter GR; Marignier R; Green AJ; Aktas O; Hartung HP; She D; Rees W; Smith M; Cimbora D; Katz E; Bennett JL;
    Lancet Neurol; 2024 Jun; 23(6):588-602. PubMed ID: 38760098
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Genome-wide loss of heterozygosity predicts aggressive, treatment-refractory behavior in pituitary neuroendocrine tumors.
    Lin AL; Rudneva VA; Richards AL; Zhang Y; Woo HJ; Cohen M; Tisnado J; Majd N; Wardlaw SL; Page-Wilson G; Sengupta S; Chow F; Goichot B; Ozer BH; Dietrich J; Nachtigall L; Desai A; Alano T; Ogilive S; Solit DB; Bale TA; Rosenblum M; Donoghue MTA; Geer EB; Tabar V
    Acta Neuropathol; 2024 May; 147(1):85. PubMed ID: 38758238
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Multi-omic analysis identifies hypoalbuminemia as independent biomarker of poor outcome upon PD-1 blockade in metastatic melanoma.
    Leek LVM; Notohardjo JCL; de Joode K; Velker EL; Haanen JBAG; Suijkerbuijk KPM; Aarts MJB; de Groot JWB; Kapiteijn E; van den Berkmortel FWPJ; Westgeest HM; de Gruijl TD; Retel VP; Cuppen E; van der Veldt AAM; Labots M; Voest EE; van de Haar J; van den Eertwegh AJM
    Sci Rep; 2024 May; 14(1):11244. PubMed ID: 38755213
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 809.